Coronavirus

Heart-related complications in children with COVID-19 are uncommon, but case reports have noted cardiogenic shock, myocarditis, pericarditis, and arrhythmias.

The companies plan to submit these data to the FDA in the coming days for an Emergency Use Authorization of a booster dose for children ages 5 through 11 in the United States.

Individuals with immunity obtained through having the disease still experienced expanded T-cell memory and immune activation after being immunized, study results show.

Obesity and a limited physical activity are key factors in post-COVID-19 recovery.

Study captures the immune effect of the third dose of the COVID-19 vaccine in patients with plasma cell disorders and blood cancers.

Roche’s Actemra/RoActemra is aimed at patients receiving systemic corticosteroids who require extracorporeal membrane oxygenation, mechanical ventilation, or supplemental oxygen.

The value of a patient-first approach and telehealth for addressing the complex health care coordination needs of patients with rare pulmonary diseases has never been more critical than during the COVID-19 pandemic.

Investigators followed men and women aged 20 to 40 years without pre-existing disease, and findings indicate that obesity and physical inactivity increase the impact of the disease.

How would you handle these patients' questions?

Despite their lower antibody responses, patients who are vaccinated receive protection from SARS-CoV-2 infection and severe disease.

An 11-fold increase in geometric mean neutralizing antibody titers was reported at 2 weeks after the second booster compared to 5 months after the first booster dose.

Access to buprenorphine among Medicaid beneficiaries was not affected during the pandemic.

Investigators also identified that a polymerase inhibitor with a unique modification largely resists its removal from the RNA by the exonuclease.

Thirty minutes of day of movement, such as walking, can help break the cycle of inflammation that causes symptoms even 6 months later.

Results of an excess-deaths analysis show that 18.2 million individuals have likely died as a result of the pandemic.

Simulations of disease spread show that wearing masks for at least 2 weeks after achieving goal of a minimum of 70% population coverage saves money and reduces deaths and hospitalizations.

Moderna expects to enroll approximately 375 participants in about 20 sites across the United States.

Pharmacy leadership remaining mindful, connected, and engaged is crucial to support the mental health needs of their staff.

Jeffery Goad, PharmD, MPH, associate dean of Academic Affairs in School of Pharmacy at Chapman University discusses the future of pharmacy when it comes to immunizations.

Moderna seeks EUA for its Spikevax COVID-19 vaccine for a fourth booster dose in individuals 18 years of age and older who have received an initial booster of any authorized or approved COVID-19 vaccine.

Michele Belcher, president of the National Community Pharmacists Association, and pharmacist and pharmacy owner at Grants Pass Pharmacy, discusses ways of transforming the pharmacy profession’s current challenges into opportunities for positive change for the profession.

Investigators call for routine monitoring of vaccination effectiveness as the pandemic continues to evolve.

Pfizer Inc and BioNTech seek approval for an additional fourth booster dose of their COVID-19 vaccine for adults 65 years of age and older who received an initial booster of any of the authorized or approved COVID-19 vaccines.

The medication is the first oral therapy specifically to treat the virus evaluated in a pediatric clinical trial.

These individuals, who were also more likely to require treatment in the intensive care unit, should get their vaccines and booster shots, investigators say.

Despite early excitement about the potential for pharmacists to prescribe COVID-19 oral antivirals, the program does not provide that ability.

Investigators advise third short for patients with weakened immune system, especially organ transplant recipients.

Effectiveness is estimated at approximately 91% against any SARS-CoV-2 infection and approximately 85% effective against asymptomatic infection, analysis results show.

Experts David Pope, PharmD, and Christina Madison, PharmD, FCCP, AAHIVP, discussed the Biden Administration's new test-to-treat plan.